BWCA
ADMS

Brenner West Capital Advisors’s Adamas Pharmaceuticals ADMS Stock Holding History

Brenner West Capital Advisors’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1,011,431
Closed -$20.2M – 19
2018
Q3 		$20.2M Buy
1,011,431
+223,708
+28% +$5.25M 2.52% 18
2018
Q2 		$20.3M Sell
787,723
-159,283
-17% -$4.41M 2.28% 19
2018
Q1 		$22.6M Sell
947,006
-323,117
-25% -$10.2M 3.09% 14
2017
Q4 		$43M Sell
1,270,123
-431,354
-25% -$12M 5.64% 8
2017
Q3 		$36M Buy
1,701,477
+281,321
+20% +$5.16M 4.3% 12
2017
Q2 		$24.8M Buy
1,420,156
+228,874
+19% +$3.78M 2.89% 13
2017
Q1 		$20.8M Sell
1,191,282
-30,181
-2% -$514K 2.1% 14
2016
Q4 		$20.6M Buy
1,221,463
+52,188
+4% +$807K 2.28% 14
2016
Q3 		$19.2M Buy
1,169,275
+152,275
+15% +$2.31M 1.72% 16
2016
Q2 		$15.4M Buy
1,017,000
+473,762
+87% +$7.81M 1.34% 17
2016
Q1 		$7.86M Buy
+543,238
New +$9.15M 0.62% 16

Other funds holding ADMS

Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

Brenner West Capital Advisors's ADMS Position: Q4 2018 in Review

Brenner West Capital Advisors sold out of Adamas Pharmaceuticals (ADMS) in Q4 2018, closing a stake of 1,011,431 shares — an estimated $20.2M sold.

Brenner West Capital Advisors first reported a position in ADMS in Q1 2016 and held it in 11 quarters. The position peaked at $43M in Q4 2017. 98 funds tracked by Wall St. Rank hold ADMS as of Q4 2018.

  • Brenner West Capital Advisors reported no remaining Adamas Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Brenner West Capital Advisors sold 1,011,431 Adamas Pharmaceuticals shares in Q4 2018, an estimated $20.2M.
  • Brenner West Capital Advisors first reported a position in Adamas Pharmaceuticals in Q1 2016 and held it in 11 quarters.
  • Brenner West Capital Advisors's Adamas Pharmaceuticals position peaked at $43M in Q4 2017.
  • 98 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q4 2018.

Based on Brenner West Capital Advisors's 13F filing for Q4 2018.